PMID- 19743938
OWN - NLM
STAT- MEDLINE
DCOM- 20091117
LR  - 20090918
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 10
IP  - 15
DP  - 2009 Oct
TI  - Pharmacotherapy of hyperglycemia.
PG  - 2415-32
LID - 10.1517/14656560903196758 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a chronic, progressive disorder that affects 
      more than 230 million people worldwide and is expected to affect 366 million by 
      2030. Both the prevalence of T2DM and the cost of its long term complications has 
      driven the focus and emphasis on treatments aimed at reducing hyperglycemia and 
      controlling hypertension and dyslipidemia. In the last 5 years new glucose 
      lowering drugs acting on novel pathways have been developed, licensed and 
      launched. These drugs include the glucagon-like peptide (GLP-1) agonists, 
      exenatide, and dipeptidyl peptidase (DPP-IV) inhibitors such as sitagliptin and 
      saxagliptin. This review describes current approaches to T2DM treatment, focusing 
      on newer agents which tend to be associated with less hypoglycemia and possible 
      weight loss, and addresses the potential roles of novel oral pharmacologic agents 
      in the late-stages of development that might provide new options for the 
      management of this disease.
FAU - Kulasa, Kristen M
AU  - Kulasa KM
AD  - Department of Medicine, University of California, Veterans Affairs San Diego 
      Healthcare System, San Diego, CA 92161, USA. kkulasa@ucsd.edu
FAU - Henry, Robert R
AU  - Henry RR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology/physiopathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/pharmacology/therapeutic use
MH  - Glucagon-Like Peptide 1/agonists
MH  - Humans
MH  - Hyperglycemia/*drug therapy/physiopathology
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/adverse effects/pharmacology/*therapeutic use
RF  - 99
EDAT- 2009/09/12 06:00
MHDA- 2009/11/18 06:00
CRDT- 2009/09/12 06:00
PHST- 2009/09/12 06:00 [entrez]
PHST- 2009/09/12 06:00 [pubmed]
PHST- 2009/11/18 06:00 [medline]
AID - 10.1517/14656560903196758 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2009 Oct;10(15):2415-32. doi: 
      10.1517/14656560903196758.